Form 4: Actinium Pharmaceuticals CFO Receives Stock Grant
Insider Transaction (Form 4)
Matthew T David, Chief Financial Officer of Actinium Pharmaceuticals, Inc., reported multiple transactions in common stock on October 14, 2026.
Summary
- Grant/award: acquired 250,000 Common Stock on October 14, 2026; holds 250,000 after (Direct).
- Grant/award: acquired 250,000 Stock Option (right to purchase) on October 14, 2026; holds 250,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Matthew T David — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-14 | Grant/award | Common Stock | 250,000 | — | — | 250,000 |
| 2026-10-14 | Grant/award | Stock Option (right to purchase) | 250,000 | — | — | 250,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-14 | Grant/award (250,000 shares) |
| 2026-10-14 | Grant/award (250,000 shares) |
Keywords
insider transaction, Form 4, ATNM, Actinium Pharmaceuticals, Inc., neutral, Matthew T David
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.